The FDA approved the second over-the-counter nasal spray with the goal of increasing access to products that can rapidly reverse the effects of opioid overdose.
The FDA has approved a new buprenorphine treatment option for people with opioid use disorder following clinical trials that tested its safety and efficacy.
This FDA Roundup includes an at-a-glance look at the latest FDA drug approvals in April and May, including treatment for menopausal hot flashes, Clostridioides difficile infection, suspected opioid...
In an effort to improve access to prevention and treatment for opioid dependence, the FDA has prioritized the approval of generic versions of medication-assisted treatment options.
The FDA’s Psychopharmacologic Drugs Advisory Committee recently reviewed and voted on whether to recommend lofexidine, a non-opioid drug, for the management of opioid withdrawal.
The FDA approved Vantrela ER tablets for the management of severe pain requiring daily opioid treatment which alternative treatment options have proven inadequate.
